Description

GLP-S

(Glucagon-Like Peptide-1 Receptor Agonist – GLP-1R)

GLP-S is a synthetic long-acting analog of human glucagon-like peptide-1 (GLP-1), developed to mimic the activity of endogenous incretin hormones that regulate glucose metabolism and energy balance. By selectively binding to and activating the GLP-1 receptor (GLP-1R), Semaglutide enhances insulin secretion, suppresses glucagon release, and delays gastric emptying in research models. Its extended half-life—achieved through structural modification that enhances albumin binding—makes Semaglutide a widely studied compound for metabolic, obesity, and glucose-regulation research as part of the incretin-based therapeutic class.

Mechanism of Action (Based on Preclinical and Clinical Research)

GLP-1 receptor activation: Stimulates glucose-dependent insulin secretion while inhibiting glucagon release.

Gastric motility modulation: Slows gastric emptying to prolong nutrient absorption and satiety.

Appetite suppression: Engages central GLP-1R pathways in the hypothalamus, influencing hunger regulation.

Metabolic efficiency: Promotes improved lipid metabolism and insulin sensitivity in experimental systems.

Extended duration: Albumin-binding modification extends biological activity up to one week in vivo.

Potential Benefits (Based on Preclinical Research)

Enhanced glucose control and insulin responsiveness Reduced food intake and body-weight modulation Improved lipid and energy metabolism markers Cardiometabolic protection observed in experimental models Studied for applications in metabolic, obesity, and endocrine research For Research Use Only. Not for Human Consumption. This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.